

ABSTRACT

The invention relates to a novel sustained release pharmaceutical formulation adapted
5 for administration by injection containing the compound
 $7\alpha\text{-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17\beta\text{-diol}}$, more
particularly to a formulation adapted for administration by injection containing the compound
 $7\alpha\text{-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17\beta\text{-diol}}$ in
solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-
10 aqueous ester solvent which is miscible in the ricinoleate vehicle.

卷之三